C4 Therapeutics, Inc. CCCC
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $12.67 (+302.1% upside)
Key Stats
- Today's Range
- $3.04 – $3.23
- 50-Day Range
- $2.59 – $4.07
- 52-Week Range
- $1.69 – $5.17
- Volume
- 3.79 million shs
- Average Volume
- 2.83 million shs
- Market Cap
- $407.08 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.27%
- Days to Cover
- 1.00
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Related Stocks
Compare head-to-head: CCCC vs AMGN·CCCC vs MRNA·CCCC vs HALO·CCCC vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.